Key Takeaways
- Discuss infertility risk at diagnosis and refer to reproductive specialists promptly.
- Provide universal fertility counseling regardless of gender identity, orientation, or financial status.
- Sperm banking before the first chemotherapy dose is the gold standard for male patients.
- Ovarian tissue cryopreservation is now an established option for adult female patients.
- Revisit fertility goals annually throughout survivorship to adjust plans as needed.
As cancer survival rates continue to climb, our focus as a medical community has shifted. It is no longer enough to simply survive; the goal is to thrive during survivorship. For many, that future includes the hope of building a family. Because chemotherapy, radiation, and surgery often pose significant risks to reproductive health, fertility preservation (FP) is now recognized as an essential right in cancer care.
Despite its importance, a gap remains: many patients do not receive information or referrals to specialists in time to take action. The 2025 ASCO Guideline Update aims to close this gap. As a patient, understanding these evidence-based recommendations allows you to advocate for your future self, ensuring your treatment plan aligns with your long-term life goals.
The Golden Rule: Early and Often
The single most important factor in successful fertility preservation is timing. To ensure you have the widest range of options, your care team should prioritize these steps:
- Initiate Discussions at Diagnosis: Expect your doctor to discuss the risk of infertility as soon as a diagnosis is made—ideally before any treatment begins.
- Universal Counseling: These conversations must happen with every patient of reproductive age, regardless of your current family size, religious beliefs, cancer prognosis, gender identity, sexual orientation, or financial status.
- Prompt Specialist Referrals: If you are interested in—or even just uncertain about—your future fertility, your team should refer you to a reproductive specialist immediately.
- Ongoing Support through Survivorship: Fertility isn't a one-and-done conversation. Your team should revisit these goals at least yearly as your treatment plan or personal desires evolve.
Research shows that having these discussions early does more than protect your biology; it reduces long-term distress and significantly improves your overall quality of life during and after recovery.
Fertility Preservation for Males: Gold Standards and Critical Windows
For postpubertal males, the path to preserving fertility is highly effective, but it is extremely sensitive to timing.
The Primary Option: Sperm Banking
Sperm cryopreservation (sperm banking) is the gold standard. It is safe, non-invasive, and provides a clear path to future biological parenthood.
Pro-Tip: While fertility specialists often suggest providing three samples to give you the most flexibility for future use, don’t let a tight treatment schedule discourage you. Even a single sample is incredibly valuable and can lead to a successful pregnancy through advanced techniques like IVF or ICSI.
Alternative Methods and What to Avoid
If you are unable to provide a sample through ejaculation, your team may offer Testicular Sperm Extraction (TESE), a surgical procedure to collect sperm directly. This can be done before therapy or during survivorship if you face long-term fertility challenges.
It is important to note that hormonal gonadoprotection is NOT recommended for males. Unlike some options for females, hormonal suppression has not been proven to protect male fertility during cancer treatment.
High-Risk Doses and the 1–2 Week Window
Certain treatments carry higher risks; for example, cyclophosphamide doses exceeding 4 g/m² are considered high-risk for male fertility. Timing is vital: Alkylating agents and radiation can induce a high risk of mutations in sperm produced within just 1 to 2 weeks after treatment begins. Therefore, it is strongly recommended that you bank sperm before your very first dose of therapy to ensure the highest genetic integrity of the sample.
Fertility Preservation for Females: Established and Emerging Paths
The 2025 update brings major news: Ovarian Tissue Cryopreservation (OTC) is now officially an established method for adult females, moving out of the experimental category.
| FP Method | Key Efficacy (Live Birth Rates)* | Considerations |
|---|---|---|
| Embryo Cryopreservation | 35% – 41% | Requires a male partner or donor sperm; requires a 2–3 week window for ovarian stimulation. |
| Oocyte Cryopreservation | 26% – 32% | Does not require sperm; ideal for single patients or those with ethical/religious objections to freezing embryos. |
| Ovarian Tissue Cryopreservation (OTC) | 19% – 32% | Established method; requires no hormonal delay; can be done immediately; only option for prepubertal girls. |
| In Vitro Maturation (IVM) | Emerging (16 live births reported) | Immature eggs are matured in a lab; useful if you cannot undergo hormonal stimulation or delay treatment. |
*Note: Success rates for patients with cancer are generally lower than those observed in the general population. Shared decision-making with your specialist is essential to set realistic expectations.
Surgical and Medical Options
- Ovarian Transposition: If you require pelvic radiation, your surgeon can move your ovaries out of the radiation field to reduce exposure.
- Conservative Gynecologic Surgery: For specific early-stage cervical or ovarian cancers, your team may offer fertility-sparing surgeries (like radical trachelectomy) that preserve the reproductive organs.
- Ovarian Suppression (GnRHa): Medical suppression (like goserelin) is not a replacement for egg or embryo freezing. However, it may be offered as an adjunct for breast cancer patients or used to suppress menstruation during oncologic emergencies.
The Post-Treatment Window
If you missed the window for preservation before treatment, you still have options. During survivorship, markers of your "ovarian reserve" (like AMH levels) often increase for 2–3 years post-treatment. This is followed by a plateau of 10–15 years of stability before a natural decline begins. This window provides a vital opportunity for survivors to pursue preservation if they haven't already.
Protecting the Youngest Patients: Children and Adolescents
Navigating fertility for children requires a delicate balance of parental consent and patient assent.
- Pubertal Patients: Boys and girls who have started puberty should be offered established methods, such as sperm banking or egg/embryo freezing.
- Prepubertal Girls: Ovarian Tissue Cryopreservation (OTC) is now the established standard of care for this group.
- Prepubertal Boys: Testicular Tissue Cryopreservation (TTC) remains experimental and should only be performed as part of a clinical trial.
Navigating the Barriers: Cost, Insurance, and Equity
Access to fertility care is a matter of equity. Currently, disparities exist based on race, socioeconomic status, and geography (particularly in rural areas with fewer specialists).
Financial Action Plan
The cost of treatment and long-term storage is a major concern for many families. Here is how to navigate it:
- Check State Mandates: Currently, 17 U.S. states and the District of Columbia have mandates requiring certain insurance plans to cover medically indicated fertility preservation.
- Review Storage Costs: Be sure to ask about the long-term costs of keeping samples frozen, as these can accumulate over decades.
- Use Patient Guides: Resources from the University of California San Diego and the Alliance for Fertility Preservation (AFP) can help you navigate insurance appeals.
- Seek Support: Organizations like LIVESTRONG and the Alliance for FP provide financial assistance and cost-saving programs specifically for patients with cancer.
Conclusion: A Checklist for Your Care Team
Fertility preservation is an essential part of your cancer journey. To ensure your goals are protected, use this checklist when speaking with your oncology team:
- Individual Risk: Based on my age and treatment (such as my specific dose of cyclophosphamide), what is my estimated risk of infertility?
- The 2-Week Window: Can we ensure my preservation (especially sperm banking) is completed within the next 7–14 days to avoid genetic damage from treatment?
- Referral: Can I speak with a reproductive endocrinologist or fertility specialist today?
- Urgent Options: If I cannot delay treatment for 2–3 weeks, can we discuss "random-start" stimulation or Ovarian Tissue Cryopreservation (OTC)?
- Long-Term Logistics: What are the estimated costs for long-term storage and the future disposition of my samples?
- Financial Counseling: Can I meet with a social worker or counselor to discuss insurance mandates in my state and available advocacy grants?
By starting these conversations today, you and your medical team can ensure that a cancer diagnosis is not the end of your future family-building dreams.